Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes.

ABSTRACT:

Background

Cholinesterase inhibitors (ChEIs) are prescribed for Alzheimer's disease (AD) and sometimes for mild cognitive impairment (MCI) without knowing underlying pathologies and its effect on cognition. We investigated the frequency of ChEI prescriptions in amyloid-negative MCI and their association with cognitive changes in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.

Methods

We included participants with amyloid positron emission tomography (PET)-negative MCI from the ADNI. We analyzed the associations of ChEI use with cognitive changes, brain volume, and cerebrospinal fluid (CSF) total tau (t-tau), hyperphosphorylated tau₁₈₁ (p-tau₁₈₁), and p-tau₁₈₁/t-tau ratio.

Results

ChEIs were prescribed in 27.4% of amyloid

SUBMITTER: Pyun JM 

PROVIDER: S-EPMC11448210 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature